Chronic Kidney Disease - CKD Care in Stages I, II and III: LDL Cholesterol Testing
The results below represent 30,079 patients with Stage I, II, or III Chronic Kidney Disease. Read More About This Measure
Chronic kidney disease (CKD) is a major public health problem. Improving outcomes for people with CKD requires a coordinated world-wide approach to prevention of adverse outcomes. Interventions during the earlier stages of kidney disease includes evaluation and management of co-morbid conditions, slowing progression of kidney disease, cardiovascular disease risk reduction, preventing and treating complications of CKD.
Disclaimer: Measures reported by WCHQ healthcare
organizations represent a specific aspect of care in relation to an
evidence-based standard, but are not clinical guidelines and do not establish
standards of care.
The National Kidney Foundation (NKF) recommends that low-density lipoprotein cholesterol (LDL-C) should be < 100 mg/dL for all patients with CKD in Stages I, II or III and that patients should have one test annually, at a minimum.
This measure shows the percentage of people 18-85 years of age with a diagnosis of CKD in stage I, II or III, excluding those with CKD in stages IV or V or with End Stage Renal Disease (ESRD) who received an LDL-cholesterol test in the measurement year.